Sun Pharma ropes in Richard Ascroft as North America CEO

Mumbai: Sun Pharma has announced the appointment of Richard Ascroft as the new North America (NAM) Chief Executive Officer (CEO).

In a statement shared via LinkedIn, the company said, “We are happy to announce Richard Ascroft has joined Sun Pharma as the new North America (NAM) Chief Executive Officer (CEO). An accomplished leader with an extensive background driving strategic growth through innovation, Richard brings more than three decades of experience to the helm of the U.S. and Canadian businesses.”
Ascroft expressed enthusiasm about his new role, stating, “I am honored to lead such a dynamic team committed to advancing Sun’s portfolio of generic, innovative and OTC medicines. The North America region is poised to bring new treatments to the market and drive significant growth for business. I look forward to building on our strong foundation, supporting patients throughout their journey and delivering the highest quality generic and innovative medicines to the people we serve.”

Prior to joining Sun, Ascroft held leadership roles at Takeda for over nine years, most recently serving as Senior Vice President, Head of US Plasma-Derived Therapies BU. He previously spent more than 22 years at Eli Lilly and Company.

Meanwhile, as previously reported by Medical Dialogues, Sun Pharma also named Kirti Ganorkar as the company’s next Managing Director, effective September 1, 2025, succeeding the company’s current Managing Director, Dilip Shanghvi. In the new role, Ganorkar will take over the responsibility for the company’s entire business and functions reporting to him.

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.

Related Posts

Maharashtra FDA issues statewide compliance order for health supplements, nutraceuticals

Commissioner of Food Safety Tukaram Mundhe said inspections, consumer complaints and surveillance had repeatedly revealed violations Repeated violations of existing food safety regulations by manufacturers and sellers of health supplements…

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

The Court observed that the alleged short supply of one tablet, coupled with the collection of ₹1.12, did not establish that the accused had sold the drug at a price…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Maharashtra FDA issues statewide compliance order for health supplements, nutraceuticals

Maharashtra FDA issues statewide compliance order for health supplements, nutraceuticals

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC